NCT05338268

Brief Summary

Background: Loneliness-a subjective emotional state characterized by the perception of social isolation-is a psychosocial factor that is associated with increased mortality, substance use, and is associated with precipitants of relapse among individuals with substance use disorders (SUD). Importantly, there are effective interventions that can be used to decrease loneliness; however, these have not been tested on Veterans with SUD who are lonely. Significance/Impact: Individuals with SUD have higher prevalence of loneliness and loneliness exacerbates pain and sleep disturbance, risk factors of relapse. Without effectively intervening on loneliness, Veterans with SUD will continue to be at high risk of relapse and will maintain problems engaging with social support, including healthcare providers-factors critical for recovery. Cognitive-behavioral therapies (CBT) has shown the strongest effects on loneliness, however, there are no interventions that are specifically designed for substance using populations who are lonely. Testing CBT for loneliness and SUD (CBT-L/SUD) has the potential to have a broad impact on addressing a critical, unmet need that commonly affects Veterans with SUD. The investigators approach of national recruitment and telehealth delivery of this intervention highlights how this this study address VHA care priorities including substance use, access to care, and telehealth. Innovation: There are no studies that have tested a loneliness intervention in Veterans with SUD who are lonely, which may neglect a broader impact on mental and physical health. This study is ideally situated to generate new and important knowledge on the association of loneliness and SUD. This study seeks to address a transdiagnostic factor, which may improve engagement with social support thereby reducing substance use. An additional innovative aspect of this study is recruitment being conducted outside the VHA. This may increase access to care among those Veterans who are especially isolated. Specific Aims: the investigators aim to: (1) refine the CBT-L/SUD manual by conducting a one-arm trial among Veterans with a SUD who report loneliness (n = 6), (2) randomize participants to receive either CBT-L/SUD (n = 15) or CBT-SUD (n = 15) to assess feasibility and acceptability among Veterans with a SUD who report loneliness. Methodology: the investigators will elicit feedback on a draft of the CBT-L/SUD manual then conduct a small single-arm trial (n = 6) for further refinement. Specifically, SUD treatment providers and Veterans with SUD will provide feedback on the draft manual, which the research team will integrate to finalize the manual for a small single-arm trial. This trial will allow us to collect feasibility of treatment delivery, and treatment satisfaction and acceptability data to further refine the manual. With the refined manual Veterans with SUD reporting loneliness will be randomized to either CBT-L/SUD (n = 15) or CBT-SUD (n = 15). The investigators will assess: (1) treatment acceptability, (2) participant adherence to treatment, and (3) therapist fidelity. The investigators will also assess outcome measure completion percentage, means and standard deviations, and level of correlation of repeated measurement of primary loneliness outcomes and secondary substance use outcomes. Implementation/Next Steps: Results from this study will provide critical feasibility and acceptability data to inform an HSR\&D Merit Award application to conduct a fully-powered randomized controlled trial. The research team will work with the VA Office of Mental Health and Suicide Prevention and the Substance Use Disorder office of the National Mental Health Program to identify implementation and dissemination efforts. For example, the investigators plan to translate findings into applied practice across various settings (e.g., primary care mental health, rehabilitation treatment programs). Additionally, this intervention may be particularly useful for behavioral telehealth centers that deliver evidence-based interventions to rural and other Veterans who have difficulty accessing VHA care.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
36

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 13, 2022

Completed
8 days until next milestone

First Posted

Study publicly available on registry

April 21, 2022

Completed
5 months until next milestone

Study Start

First participant enrolled

September 30, 2022

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
1 year until next milestone

Results Posted

Study results publicly available

January 15, 2026

Completed
Last Updated

February 18, 2026

Status Verified

February 1, 2026

Enrollment Period

2.3 years

First QC Date

April 13, 2022

Results QC Date

December 23, 2025

Last Update Submit

February 4, 2026

Conditions

Keywords

LonelinessSubstance use disorderssocial isolationdrug use

Outcome Measures

Primary Outcomes (1)

  • Mean Change in Loneliness From Baseline to 1-month Post-treatment Follow-up

    Loneliness will be measured using the UCLA Loneliness Scale. A 20-item scale designed to measure one's subjective feelings of loneliness as well as feelings of social isolation. Participants rate each item as 1 (never), 2 (rarely), 3 (sometimes) or 4 (often). The scores range from 20-80 with higher scores indicating worse outcome.

    baseline to 1-month post-treatment follow-up

Secondary Outcomes (3)

  • Mean Change in Number of Days of Substance Use From Baseline to 1-month Post-treatment Follow-up

    baseline to 1-month post-treatment follow-up

  • Mean Change in Percent Days Abstinent From Baseline to 1-month Post-treatment Follow-up

    baseline to 1-month post-treatment follow-up

  • Mean Change in Social Interactions Baseline to 1-month Post-treatment Follow-up

    baseline to 1-month post-treatment follow-up

Other Outcomes (2)

  • Mean Change in Depression Baseline to 1-month Post-treatment Follow-up

    baseline to 1-month post-treatment follow-up

  • Mean Change in Anxiety Baseline to 1-month Post-treatment Follow-up

    baseline to 1-month post-treatment follow-up

Study Arms (2)

CBT for Loneliness

EXPERIMENTAL

CBT focused on social relationships and loneliness delivered over the course of 8, \~45 minute sessions delivered via telehealth.

Behavioral: CBT for Loneliness

CBT for Substance Use Disorder

ACTIVE COMPARATOR

CBT focused on substance use disorders delivered over the course of 8, \~45 minute sessions delivered via telehealth.

Behavioral: CBT for Substance Use Disorder

Interventions

CBT focused on social relationships and loneliness delivered over the course of 8, \~45 minute sessions delivered via telehealth.

CBT for Loneliness

CBT focused on substance use disorders delivered over the course of 8, \~45 minute sessions delivered via telehealth.

CBT for Substance Use Disorder

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participants must be ages 18+,
  • understand English,
  • have access to a phone or computer,
  • screen positive for an active, at least moderate SUD. SUD include alcohol, marijuana, opioids, cocaine, other psychomotor stimulants (methamphetamine, amphetamines), and sedative/hypnotic/anxiolytic use disorders.
  • Participants will need to screen positive for loneliness.

You may not qualify if:

  • Participant with significant cognitive impairment will be excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

VA Finger Lakes Healthcare System, Canandaigua, NY

Canandaigua, New York, 14424-1159, United States

Location

MeSH Terms

Conditions

Substance-Related DisordersSocial Isolation

Condition Hierarchy (Ancestors)

Chemically-Induced DisordersMental DisordersSocial BehaviorBehavior

Results Point of Contact

Title
Lisham Ashrafioun
Organization
VA Finger Lakes Healthcare System

Study Officials

  • Lisham Ashrafioun, PhD

    VA Finger Lakes Healthcare System, Canandaigua, NY

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
The outcomes assessors will not know what condition that the participant was allocated to, nor will the statistician who is one of the co-investigators.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Participants are randomized to one of two interventions.
Sponsor Type
FED
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 13, 2022

First Posted

April 21, 2022

Study Start

September 30, 2022

Primary Completion

December 31, 2024

Study Completion

December 31, 2024

Last Updated

February 18, 2026

Results First Posted

January 15, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

Locations